Quantum BioPharma Ltd. Advances MS Treatment with CDMO Agreement for Lucid-MS

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has announced a pivotal development in its quest to address multiple sclerosis (MS) through its subsidiary, Huge Biopharma Australia Pty Ltd. The company has entered into an agreement with a leading contract development and manufacturing organization (CDMO) to produce an oral formulation of Lucid-MS for its upcoming Phase 2 clinical trial. This trial aims to evaluate the efficacy of Lucid-MS in restoring mobility in individuals suffering from MS, a condition that affects millions worldwide.

Lucid-MS represents a breakthrough as a patented, first-in-class, non-immunomodulatory neuroprotective compound. Its potential lies in its demonstrated ability to prevent demyelination, a critical factor in the progression of MS and other neurodegenerative diseases. The agreement with the CDMO is a crucial milestone towards filing an Investigational New Drug (IND) application with the FDA for Lucid-21-302 in MS, marking a significant step in the drug's development pathway.

The implications of this development are profound for the MS community and the broader field of neurodegenerative disease treatment. With a decade of preclinical studies showing promising results, including the restoration of walking ability in animal models, Lucid-MS could offer a new hope for patients. The move to Phase 2 trials underscores Quantum BioPharma's commitment to advancing innovative treatments for challenging conditions.

For more information on Quantum BioPharma's groundbreaking work and its portfolio of innovative assets, visit https://ibn.fm/y8RRY. This development not only highlights the company's dedication to addressing unmet medical needs but also its strategic approach to leveraging partnerships to accelerate the delivery of potential therapies to the market.